Reprogramming the course of cancer and diabetes, Austin-based Genprex is on the cutting edge of technologies to address the biggest health concerns
Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options
Genprex, a clinical-stage gene therapy company, has recently released groundbreaking data from a non-human primate study evaluating a novel gene therapy to treat Type 1 diabetes.
With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D.
Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies
Company to Showcase its Innovate Gene Therapy Programs in Oncology and Diabetes
Designed and Secured by Barsec